Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia

Nature

Volumn 513, Issue 7519, 2014, Pages 512-516

  Dail, Monique ^a   Wong, Jason ^a   Lawrence, Jessica ^a   O'Connor, Daniel ^a   Nakitandwe, Joy ^b   Chen, Shann Ching ^b   Xu, Jin ^a   Lee, Leslie B ^c   Akagi, Keiko ^d   Li, Qing ^e   Aster, Jon C ^f   Pear, Warren S ^g   Downing, James R ^b   Sampath, Deepak ^c   Shannon, Kevin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c GENENTECH INC   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA SECRETASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYLPIPERAZIN 1 YLMETHYL) 4 MORPHOLIN 4 YLTHIENO(3,2 D)PYRIMIDINE; 2-(1H-INDAZOL-4-YL)-6-(4-METHANESULFONYLPIPERAZIN-1-YLMETHYL)-4-MORPHOLIN-4-YLTHIENO(3,2-D)PYRIMIDINE; BENZAMIDE DERIVATIVE; DIPHENYLAMINE; DRUG DERIVATIVE; INDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

CELL ORGANELLE; DATA SET; DRUG RESISTANCE; ENZYME ACTIVITY; GENE; INHIBITOR; MUTATION; RODENT; SIGNALING;

ARTICLE; CROSS RESISTANCE; DOWN REGULATION; DRUG EFFICACY; ENZYME REPRESSION; GENE TARGETING; IN VIVO STUDY; LEUKEMIA RELAPSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; UPREGULATION; ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL; C57BL MOUSE; CELL CLONE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; GENETICS; MALE; METABOLISM; ONCOGENE RAS; PATHOLOGY; PROTEIN TERTIARY STRUCTURE;

MUS;

ANIMALS; BENZAMIDES; CLONE CELLS; DIPHENYLAMINE; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENES, RAS; INDAZOLES; MALE; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84908379567     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature13495     Document Type: Article

References (33)

1. Aster, J. C., Blacklow, S. C. & Pear, W. S. Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J. Pathol. 223, 263-274 (2011).
2. Gutierrez, A. et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 114, 647-650 (2009).
3. Tosello, V. & Ferrando, A. A. The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy. Ther. Adv. Hematol. 4, 199-210 (2013).
4. Blackburn, J. S. et al. Clonal evolution enhances leukemia-propagating cell frequency in T cell acute lymphoblastic leukemia through Akt/mTORC1 pathway activation. Cancer Cell 25, 366-378 (2014).
5. Piovan, E. et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell 24, 766-776 (2013).
6. Palomero, T. et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nature Med. 13, 1203-1210 (2007).
7. Trinquand, A. et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classificationofadult T-cell acute lymphoblastic leukemia: a Group for Research in Adult AcuteLymphoblastic Leukemia study. J. Clin. Oncol. 31, 4333-4342 (2013).
8. Jotta, P. Y. et al. Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia. Leukemia 24, 239-242 (2010).
9. Clappier, E. et al. Clonal selection in xenografted humanT cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J. Exp. Med. 208, 653-661 (2011).
10. Folkes, A. J. et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem. 51, 5522-5532 (2008).
11. G12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proc. Natl Acad. Sci. USA 107, 5106-5111 (2010).
12. Shieh, A. et al. Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo. Blood (2013).
13. Lauchle, J. O. et al. Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature 461, 411-414 (2009).
14. Sos, M. L. et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc. Natl Acad. Sci. USA 106, 18351-18356 (2009).
15. Brown, A. P., Carlson, T. C., Loi, C. M. & Graziano, M. J. Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemother. Pharmacol. 59, 671-679 (2007).
16. Wendorff, A. A. et al. Hes1 is a critical but context-dependentmediator of canonical Notch signaling in lymphocyte development and transformation. Immunity 33, 671-684 (2010).
17. Mansour, M. R. et al. Notch-1 mutations are secondary events in some patients with T-cell acute lymphoblastic leukemia. Clin. Cancer Res. 13, 6964-6969 (2007).
18. Mullighan, C. G. et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322, 1377-1380 (2008).
19. Corcoran, R. B., Settleman, J. & Engelman, J. A. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget 2, 336-346 (2011).
20. 308) dephosphorylation through modulation of the PP2A phosphatase in PTEN-null T-cell acute lymphoblastic leukemia cells. J. Biol. Chem. 288, 22836-22848 (2013).
21. Gutierrez, A. et al. Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. J. Exp. Med. 208, 1595-1603 (2011).
22. Aster, J. C. & Blacklow, S. C. Targeting the Notch pathway: twists and turns on the road to rational therapeutics. J. Clin. Oncol. 30, 2418-2420 (2012).
23. Zhang, J. et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481, 157-163 (2012).
24. Tzoneva, G. et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nature Med. 19, 368-371 (2013).
25. Gutierrez, A. & Look, A. T. NOTCH and PI3K-AKT pathways intertwined. Cancer Cell 12, 411-413 (2007).
26. Lobry, C., Oh, P. & Aifantis, I. Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J. Exp. Med. 208, 1931-1935 (2011).
27. Zuber, J. et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 25, 1628-1640 (2011).
28. Hawley, R. G., Lieu, F. H., Fong, A. Z. & Hawley, T. S. Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1, 136-138 (1994).
29. Aster, J. C. et al. Oncogenic forms of NOTCH1 lacking either the primary binding site for RBP-Jκ or nuclear localization sequences retain the ability to associate with RBP-Jκ and activate transcription. J. Biol. Chem. 272, 11336-11343 (1997).
30. Weng, A. P. et al. Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol. Cell. Biol. 23, 655-664 (2003).
31. Maillard, I. et al. Mastermind critically regulates Notch-mediated lymphoid cell fate decisions. Blood 104, 1696-1702 (2004).
32. Kent, W. J. BLAT-the BLAST-like alignment tool. Genome Res. 12, 656-664 (2002).
33. Gentleman, R. C. et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5, R80 (2004).